Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 5th edition, 486 pages

Free download


  Breast Cancer

  Free Subscription


Articles published in Nat Rev Clin Oncol

Retrieve available abstracts of 37 articles:
HTML format



Single Articles


    October 2020
  1. SASIENI PD, Sawyer EJ
    Intraoperative radiotherapy for early breast cancer - insufficient evidence to change practice.
    Nat Rev Clin Oncol. 2020 Oct 21. pii: 10.1038/s41571-020-00444.
    PubMed    


    July 2020
  2. ROMERO D
    Myocardial infarction promotes breast cancer recurrence.
    Nat Rev Clin Oncol. 2020 Jul 24. pii: 10.1038/s41571-020-0418.
    PubMed    


    June 2020
  3. PASHAYAN N, Antoniou AC, Ivanus U, Esserman LJ, et al
    Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
    Nat Rev Clin Oncol. 2020 Jun 29. pii: 10.1038/s41571-020-0412.
    PubMed     Abstract available


  4. PASHAYAN N, Antoniou AC, Ivanus U, Esserman LJ, et al
    Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
    Nat Rev Clin Oncol. 2020 Jun 18. pii: 10.1038/s41571-020-0388.
    PubMed     Abstract available


  5. NAGAR H, Formenti SC
    Cancer and COVID-19 - potentially deleterious effects of delaying radiotherapy.
    Nat Rev Clin Oncol. 2020;17:332-334.
    PubMed    


  6. SCARANTI M, Cojocaru E, Banerjee S, Banerji U, et al
    Exploiting the folate receptor alpha in oncology.
    Nat Rev Clin Oncol. 2020;17:349-359.
    PubMed     Abstract available


    April 2020
  7. KILLOCK D
    Moving pembrolizumab forwards.
    Nat Rev Clin Oncol. 2020;17:196.
    PubMed    


    March 2020
  8. SHIEH Y, Ziv E, Kerlikowske K
    Interval breast cancers - insights into a complex phenotype.
    Nat Rev Clin Oncol. 2020;17:138-139.
    PubMed    


  9. KILLOCK D
    AI outperforms radiologists in mammographic screening.
    Nat Rev Clin Oncol. 2020;17:134.
    PubMed    


  10. SIDAWAY P
    HER2-targeted agents overcome resistance.
    Nat Rev Clin Oncol. 2020;17:133.
    PubMed    


    February 2020
  11. BYRNE A, Savas P, Sant S, Li R, et al
    Tissue-resident memory T cells in breast cancer control and immunotherapy responses.
    Nat Rev Clin Oncol. 2020 Feb 28. pii: 10.1038/s41571-020-0333.
    PubMed     Abstract available


    December 2019
  12. GOUTSOULIAK K, Veeraraghavan J, Sethunath V, De Angelis C, et al
    Towards personalized treatment for early stage HER2-positive breast cancer.
    Nat Rev Clin Oncol. 2019 Dec 13. pii: 10.1038/s41571-019-0299.
    PubMed     Abstract available


  13. KILLOCK D
    CDK4/6 inhibitors prolong OS.
    Nat Rev Clin Oncol. 2019;16:722.
    PubMed    


    November 2019
  14. PONDE N, de Azambuja E
    PERSEPHONE - implications for clinical practice in 2019.
    Nat Rev Clin Oncol. 2019;16:663-664.
    PubMed    


    October 2019
  15. KILLOCK D
    Personalized MRD assays and therapy?
    Nat Rev Clin Oncol. 2019;16:593.
    PubMed    


    September 2019
  16. OH DY, Bang YJ
    HER2-targeted therapies - a role beyond breast cancer.
    Nat Rev Clin Oncol. 2019 Sep 23. pii: 10.1038/s41571-019-0268.
    PubMed     Abstract available


    August 2019
  17. SIDAWAY P
    Alpelisib effective in advanced-stage disease.
    Nat Rev Clin Oncol. 2019;16:466.
    PubMed    


  18. KILLOCK D
    Chemotherapy as a TONIC to invigorate PD-1 inhibition in TNBC.
    Nat Rev Clin Oncol. 2019;16:464.
    PubMed    


  19. ROMERO D
    HDAC inhibitors tested in phase III trial.
    Nat Rev Clin Oncol. 2019;16:465.
    PubMed    


    June 2019
  20. SIDAWAY P
    Fulvestrant enables better outcomes.
    Nat Rev Clin Oncol. 2019;16:337.
    PubMed    


  21. BRADLEY CA
    Brain metastases respond to neratinib plus capecitabine.
    Nat Rev Clin Oncol. 2019;16:336.
    PubMed    


    May 2019
  22. CUZICK J
    Predicting late recurrence in ER-positive breast cancer.
    Nat Rev Clin Oncol. 2019 May 15. pii: 10.1038/s41571-019-0228.
    PubMed    


  23. D'ABREO N, Adams S
    Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?
    Nat Rev Clin Oncol. 2019 May 3. pii: 10.1038/s41571-019-0216.
    PubMed    


  24. ROMERO D
    Healthier bones and less recurrence with denosumab.
    Nat Rev Clin Oncol. 2019;16:272.
    PubMed    


    April 2019
  25. SIDAWAY P
    Early PET response predicts complete response.
    Nat Rev Clin Oncol. 2019;16:208.
    PubMed    


  26. KILLOCK D
    CTCs 'piggyback' off neutrophils.
    Nat Rev Clin Oncol. 2019;16:208.
    PubMed    


    December 2018
  27. RICHMAN J, Dowsett M
    Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer.
    Nat Rev Clin Oncol. 2018 Dec 18. pii: 10.1038/s41571-018-0145.
    PubMed     Abstract available


    September 2018
  28. PONDE NF, Zardavas D, Piccart M
    Progress in adjuvant systemic therapy for breast cancer.
    Nat Rev Clin Oncol. 2018 Sep 11. pii: 10.1038/s41571-018-0089.
    PubMed     Abstract available


    June 2018
  29. SIDAWAY P
    Ribociclib effective in HR(+), HER2(-) breast cancer.
    Nat Rev Clin Oncol. 2018 Jun 21. pii: 10.1038/s41571-018-0059.
    PubMed    


    March 2018
  30. SIDAWAY P
    Breast cancer: Changes in clonal dynamics predict response to palbociclib.
    Nat Rev Clin Oncol. 2018 Mar 20. pii: nrclinonc.2018.
    PubMed    


  31. SIDAWAY P
    Breast cancer: Fibroblast subtypes alter the microenvironment.
    Nat Rev Clin Oncol. 2018 Mar 6. pii: nrclinonc.2018.
    PubMed    


    February 2018
  32. ROMERO D
    Breast cancer: Metronomic chemotherapy for elderly and/or frail patients.
    Nat Rev Clin Oncol. 2018 Feb 27. pii: nrclinonc.2018.
    PubMed    


  33. ROMERO D
    Breast cancer: Recurrent fusions in endocrine-resistant disease.
    Nat Rev Clin Oncol. 2018 Feb 6. pii: nrclinonc.2018.
    PubMed    


    January 2018
  34. VAZ-LUIS I, Partridge AH
    Exogenous reproductive hormone use in breast cancer survivors and previvors.
    Nat Rev Clin Oncol. 2018 Jan 23. pii: nrclinonc.2017.
    PubMed     Abstract available


    December 2017
  35. PEREZ-GARCIA J, Cortes J
    Breast cancer in 2017: Spurring science, marking progress, and influencing history.
    Nat Rev Clin Oncol. 2017 Dec 12. pii: nrclinonc.2017.
    PubMed    


    October 2017
  36. SIDAWAY P
    Breast Cancer: Abemaciclib effective in combination with aromatase inhibition.
    Nat Rev Clin Oncol. 2017 Oct 17. doi: 10.1038/nrclinonc.2017.
    PubMed    


  37. SIDAWAY P
    Breast cancer: LAG3 expression indicates favourable outcomes.
    Nat Rev Clin Oncol. 2017 Oct 10. doi: 10.1038/nrclinonc.2017.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: